Effect of oral L-arginine administration for three weeks in two kidney-two clip hypertensive rats. 2000

I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
Departamento de Ciencias Fisiológicas, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. idelariv@fmed.uba.ar

Nitric oxide (NO) has been identified as an effective vascular relaxant. This study analyses the contribution of the precursor L-arginine (L-arg) by oral administration in two kidney-two clip hypertension in the rat (2K-2C). Two groups were studied: sham (SH, n=21) and hypertensive (HT, n=15). After 4 weeks of surgery, a group of rats remained as controls (SHc and HTc, respectively), while others were supplemented with L-arg (1.25 g/L) in drinking water (SHa and HTa) for 3 weeks. Blood pressure was significantly increased in 2K-2C rats but remained unchanged after L-arg treatment. Plasma nitrite/nitrate concentrations were not different among groups. The contractile response of aorta to KCl, serotonin and the protein kinase C (PKC) stimulant, phorbol 12,13-dibutyrate (PDBu) was also evaluated. Higher contractile responses to PDBu (p<0.001) and lower relaxation to acetylcholine (Ach 10(-6) M, p<0.05 and 10(-5)M, p<0.02) were observed in aortic rings of HTc vs SHc; L-arg supplementation significantly diminished tension development to all agonists (p<0.05) but failed to modify the lower relaxation to Ach in HTa. Thromboxane (TxA(2)) - synthesis in rings of HTc was higher than in SHc under basal conditions (p<0.05). In the groups with supplement of L-arg, PDBu significantly stimulated prostacyclin (PGI(2)) synthesis more in HTa rats than in SHa ones (p<0.05). To conclude: 1) L-arg fails to modify hypertension development in 2K-2C rats; and 2) L-arg exerts a beneficial effect on the vascular wall, by reducing contractility in rings from HTa rats; it also improved PGI(2) synthesis under PDBu stimulation. 3) greater PKC activation and TxA(2) production rather than lower NO availability might result in systemic hypertension in 2K-2C rats.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007552 Isotonic Solutions Solutions having the same osmotic pressure as blood serum, or another solution with which they are compared. (From Grant & Hackh's Chemical Dictionary, 5th ed & Dorland, 28th ed) Solutions, Isotonic
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009566 Nitrates Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. Nitrate
D009573 Nitrites Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M Nitrite
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D011189 Potassium Chloride A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA. Slow-K,Chloride, Potassium
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri

Related Publications

I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
June 1991, Hypertension (Dallas, Tex. : 1979),
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
August 1997, European journal of pharmacology,
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
February 1983, Chest,
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
December 2007, Ultrasound in medicine & biology,
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
September 2004, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society,
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
August 2013, Bosnian journal of basic medical sciences,
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
December 1984, The American journal of physiology,
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
October 1989, Hypertension (Dallas, Tex. : 1979),
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
January 1992, Polish journal of pharmacology and pharmacy,
I J de la Riva, and M I Rosón, and G W Vega, and N Speziale, and L E Albornoz, and E L Palumbo, and A J Ferrero, and P F Damiano
July 1997, European journal of pharmacology,
Copied contents to your clipboard!